Headquartered in Dallas, TX Fiscal year ends December NYSE: KMB kimberly-clark.com
Kimberly-Clark Corporation (Nasdaq: KMB) is a global personal care and consumer health company serving consumers in more than 175 countries.
It acquired Kenvue on November 2, 2026, adding consumer health brands to its portfolio. The combined portfolio includes Huggies, Kleenex, Cottonelle, Scott, Kotex and Depend alongside Listerine, Neutrogena, Tylenol and Johnson's.
Continuing operations are reported in two segments:
- North America, which includes Family Care and Professional categories;
- International Personal Care, with markets including China, South Korea, Indonesia and Enterprise Markets.
On July 1, 2026, the company completed the IFP Transaction. It contributed its International Family Care and Professional business to the Arbex Joint Venture with Suzano, now reported as discontinued operations. Kimberly-Clark holds an equity interest in the joint venture and supplies it under supply agreements.
The company also holds an equity stake in Kimberly-Clark de Mexico. It is executing a 2024 Transformation Initiative aimed at productivity and innovation-led growth. It has paid a dividend for 92 consecutive years and raised it for 54 consecutive years. Updated
AI infrastructure names are taking the whole top of the board at the open, led by CoreWeave's 10.5% jump the morning after its Q3 earnings filing. The downside is narrow by comparison: outside GoPro's 13% drop, no loser is worse than 4.3%.
Kimberly-Clark just put its North America chief and growth boss on the insider tape, meaning the executive steering the company's biggest profit region and its transformation agenda now has every trade disclosed in public. For a $68 billion consumer staple deep in restructuring, those filings become a running read on how the person closest to the plan views it.
Kimberly-Clark just added a new name to its insider roster, and the timing matters: the $68 billion consumer-goods maker is mid-transformation, leaning on productivity gains to offset soft sales. Every Form 4 that follows from this desk is now a read on how leadership sees that turnaround.
Kimberly-Clark is stocking its executive bench as it builds the organization for the pending Kenvue acquisition, and the marketing seat is now filed at the SEC. A new Form 3 is the first look at how the $68 billion consumer giant is wiring leadership for that integration.
Kimberly-Clark just put a technology executive in charge of consumer growth, a newly created seat that signals the $68 billion staples maker is betting its next sales lift comes from digital and AI-driven innovation rather than price hikes. The first Form 3 makes the Powering Care push a staffed priority.
The sixth straight earnings beat lands three days after the $49 billion Kenvue deal closed, putting the debt load at the center of the story. Organic sales fell 1.3%, and management still reaffirmed its 2026 standalone outlook.
A new board voice lands at the $67.5 billion tissue and personal care maker just as it absorbs the Kenvue acquisition and reshapes its operations around digital. Form 3 filings like this one mark the start of a trail worth following for signs of conviction at the top.
The former Domino's Pizza CEO now has a seat at the table at a $66.8 billion staples giant midway through a multiyear transformation and the Kenvue integration. Board additions rarely move the tape, but they signal where management wants outside pressure applied next.
The man who ran CVS Health for nearly a decade is now helping steer a $66.8 billion consumer staples giant in the middle of its Powering Care transformation. Merlo's retail and healthcare distribution background lands at Kimberly-Clark just as the company reshapes its portfolio toward higher-value growth.
Kenvue is going quiet, skipping guidance and the conference call with the Kimberly-Clark combination near completion, leaving a fourth straight quarter of sales growth to speak for itself. Revenue beat estimates and adjusted earnings came in just under expectations, with a 29.4% effective tax rate weighing on results.
A strong October quarter sent P&G shares climbing toward a 52-week high, yet oil prices and shrinking margins threaten the rally. Can volume-led growth and a looming Investor Day outrun the commodity…
Converting everything at once looks simple, but one lump-sum move can trigger a steep tax bracket and a Medicare surprise two years later. A smarter timing window before forced withdrawals begin changes…
Kimberly-Clark swallowed Kenvue, Public Storage absorbed National Storage Affiliates, and two apartment REITs fused into one. Now each board decides what shareholders get paid, and the integration costs, debt loads, and dilution…
Some brands simply outlast every fad. A Coke at the ballpark, a jug of Tide in the laundry room and a box of Kleenex on the nightstand have been fixtures in American…
Kimberly-Clark has raised its payout for 54 straight years, yet last year's cash flow barely covered the check. With the Kenvue deal now closed and debt climbing, a few telltale signs will…
Chris Lange Bond coupons never grow, but these four payers just handed shareholders a raise. One has a cash-rich balance sheet, one faces a $49 billion gamble, one is heading for a breakup, and…
Every quarter, dividends quietly buy shares you never planned to own while your checking account sits untouched. One overlooked brokerage setting changes that, but the tax rules and the compounding trade-off might…
Every December, retirees sell shares they would rather keep just to satisfy an IRS deadline they never asked for. A three-holding portfolio built around yield might change that math entirely, but only…
Kimberly-Clark is absorbing one of the most recognizable brand portfolios in consumer health, and the deal reshapes what investors own across three different indexes at once. What happens to your dividend income…
Wall Street holds or sells every one of these four blue chips, yet each has raised its dividend every single year and yields at least 4.35%. Find out why the analyst skepticism…
Four household names spread across pipelines, tobacco, banking, and consumer staples are paying yields that most blue chips never come close to, but a big yield number means nothing if the cash…
Pre-Market Stock Futures: Futures are trading lower as we get to wrap up a busy week, and what a week it has been. After a solid mid-week rally on Wednesday that had…
Jim Cramer called Kimberly-Clark hated, but the real story behind its dividend streak, its free cash flow, and a social media disinformation campaign in China raises harder questions than Cramer let on.
Both Kimberly-Clark and Clorox are mid-overhaul, both pay yields above 4.5%, and both have dividend payout ratios that leave almost no cushion. When two consumer staples giants look this similar on paper,…
A 52-year raise streak sounds safe until you put it next to a 7.8% yield, a reset dividend, and a consumer staples giant whose payouts free cash flow still covers even as…
Kimberly-Clark Corporation (Nasdaq: KMB) is a global personal care and consumer health company serving consumers in more than 175 countries. It acquired Kenvue on November 2, 2026, adding consumer health brands to its portfolio.
24/7 Wall St.'s 12-month price target for KMB is $128.87, rated Buy. The Wall Street consensus target is $118.53. KMB price prediction →
